This mechanism of action (MoA) animation was created for Bristol Myers Squibb to visually convey the science behind their oncology combination treatment, OPDIVO® (nivolumab), and YERVOY® (ipilimumab). This drug combination is indicated for the treatment of advanced melanoma.
OPDIVO® + YERVOY® are two immunotherapies that BMS has combined to harness the body’s immune system to fight cancer. The animation tells the story of the combined medications and how they help the body attack cancer by shrinking tumors.
OPDIVO® is a monoclonal antibody, an anti-PD-1 drug, that promotes the tumor-killing effects of T-cells. YERVOY® is also a monoclonal antibody, an anti-CTLA-4 drug, that helps strengthen the immune system by promoting the function and growth of T-cells. The combination of these antibodies promotes an enhanced anti-tumor response.
This animation is hosted on the OPDIVO® HCP website for healthcare professionals to discover how these drugs work collectively.
